It is clear that sudden unexpected death in epilepsy (SUDEP) is mainly a problem for people with refractory epilepsy, but our understanding of the best way to its prevention is still incomplete. Although the pharmacological treatments available for epilepsies have expanded, some antiepileptic drugs are still limited in clinical efficacy. In the present paper, we described an experience with vagus nerve stimulation (VNS) treatment by opening space and providing the opportunity to implement effective preventative maps to reduce the incidence of SUDEP in children and adolescents with refractory epilepsy.
VIEWS AND REVIEWS

Epileptologists probe vagus nerve stimulation in children with refractory epilepsy: a promise against sudden unexpected death in epilepsy
Epileptologistas indicam a estimulação do nervo vago em crianças com epilepsia refratária: uma promessa contra a morte súbita em epilepsia Worldwide, epilepsy is considered the most common serious neurological condition that knows no geographic, social, or racial boundaries, occurring in men and women and affecting people of all ages, though it affects more frequently young people in the first two decades of life and those over the age of 60 1, 2 . In a more specific way, a major proportion of people with epilepsy falls in the pediatric group (18 years-old or less), and approximately 25% of those patients have medically intractable epilepsy 3 . Furthermore, only 10 to 20% of the children with epilepsy, who remain presenting active epilepsy in adulthood, will have spontaneous seizure remission, suggesting that early attempts to control epilepsy should be pursuit [4] [5] [6] . Often, epilepsy is still seen as a benign condition in which individuals only have seizures. Unfortunately, the story is not as simple as it seems. Epilepsy is a malignant condition that has a high rate of premature death compared with the general population [7] [8] [9] . Most of the excess death is due to the underlying disease causing epilepsy, however some is epilepsy-related, including trauma, suicide, aspiration pneumonia, status epilepticus, mostly due to sudden unexpected death in epilepsy (SUDEP), which is a leading cause of mortality in people with epilepsy [7] [8] [9] . From an epidemiological standpoint, results from a US population-based study indicate that the risk of sudden death in people with epilepsy is estimated to be at least 20 times higher than that of the general population 10 . In general terms, SUDEP is responsible for 7.5 to 17% of all deaths in people with epilepsy, and it has an incidence among adults between 1:500 and 1:1,000 patient-years 11 . Concerning risk factors, the main currently described are refractoriness of the epileptic condition, presence of convulsive seizures, early onset of epilepsy, antiepileptic medication (polytherapy with antiepileptic drugs), young age, and duration of the seizure disorder 9, 12, 13 . The causes of SUDEP are still unknown, but researches consistently suggest that the main mechanism for SUDEP is autonomic dysregulation, i.e., cardiac and respiratory abnormalities during and after seizures 9, [12] [13] [14] . In addition, it is clear that SUDEP is mainly, but not exclusively, a problem for people with uncontrolled epilepsy 13 , but our understanding of the best way to its prevention is still incomplete. Strict evidence still lacks for its effectiveness, but epidemiologic and observational data seem to suggest some measures to minimize the risk of SUDEP, and these include: good seizure control, stress reduction, participation in physical activity and sports (with appropriate professional supervision), dietary management (omega-3 supplementation), night supervision, family members' knowledge of cardiopulmonary resuscitation techniques, and the basics of defibrillator use 13, 15, 16 . Despite the great scientific advances of SUDEP over the past two decades, most of the information described above was conducted in adults and, unfortunately, we still have little data regarding SUDEP in children 17, 18 . According to the excellent review article published recently by Sascha Meyer et al. 18 , epileptic children and adolescents with refractory seizures, early-onset epilepsy, and developmental retardation seem to be at higher risk for SUDEP. Following this line of reasoning, we reviewed the occurrence of SUDEP in children in our epilepsy unit over an eight-year period 19 . Our study evaluated SUDEP incidence in a cohort of children aged between 0 and 18 years-old, who were evaluated in the Clinical Hospital of Ribeirão Preto in 2000 and followed-up until June, in 2008. Briefly, from the 835 patients evaluated, 12 had suffered SUDEP and nearly all of the SUDEP cases in our children were related to chronic uncontrolled epilepsy (daily -50.0%, two to four/weeks -41.7%, monthly -8.3%). Furthermore, the high frequency of generalized tonic-clonic seizures and polytherapy with antiepileptic drugs may also be highlighted as risk factors in our study 19 . By assessing the information set out so far and considering that although the availability of pharmacological and surgical treatment for epilepsy has expanded, antiepileptic drugs and some resective procedures are still limited in clinic efficacy. Thus, the desire to find alternative treatments for untreatable epilepsy has led epileptologists to use therapeutic devices in order to minimize the occurrence of SUDEP. For that, vagus nerve stimulation (VNS) may receive a prominent role in this scenario. It has been established that patients with medically intractable epilepsy, who are not candidates for epilepsy surgery, could benefit from neurostimulation 20 . Hence, VNS therapy is the only neurostimulation modality approved by the Food and Drug Administration (FDA). It has been shown to be efficacious and as well tolerated in children and adolescents as in adults 20 . Furthermore, it has been shown to be a cost-effective treatment, reducing direct medical costs, and improving health-related quality of life measures 20 . In a similar way, we have the same positive experience with VNS therapy.
In brief, we analyzed 36 patients up to 18 years-old, with medically intractable epilepsy submitted to VNS implantation. In these patients, a reduction of at least 50% of seizures was achieved in 61.3% of the cases and 12.1% of the individuals had more than 90% of seizure frequency reduction. Furthermore, 47.2% of the patients needed frequently hospitalization before VNS implantation and, in follow-up, this number dropped out to 8.3%. In sum, we concluded that VNS demonstrated to be effective in reducing seizure frequency and reducing the need of hospitalization in children with some refractory epilepsies, and it should be considered as an option even in countries with limited resources.
On the whole, it seems reasonable to assume that the risk of sudden death is clearly increased in the epilepsy population, and SUDEP is the most important direct epilepsy-related cause of death. The establishment of SUDEP mechanisms is important for starting preventative measures for SUDEP and for striving to the best control of seizures. Finally, these VNS results open space and provide us the opportunity of implementing effective preventative maps to reduce SUDEP incidence in children and adolescents with refractory epilepsy.
